Cantor Equity Partners, Inc. shares fall 2.41% intraday as Vertex Pharmaceuticals' price targets are adjusted by multiple analysts.

Cantor Equity Partners, Inc. declined 2.41% in intraday trading. The drop in stock price may be attributed to the recent news events where multiple financial institutions, including Morgan Stanley, RBC, and Bernstein, adjusted their price targets on Vertex Pharmaceuticals, with some reducing their targets significantly. Additionally, Ranpak Holdings Corp. reported a net loss for the second quarter of 2025, which could have contributed to the overall negative sentiment in the market.